15 terminated. 15 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 15 | Terminated 15 |
Follow Mycoses: new trials by email Literature Review of Mycoses trials Research Report on Mycoses
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Itraconazole in the Management of Superficial Fungal Infections in India Itraconazole - Mycoses | Phase 4 | Terminated | Janssen Research & Development, LLC | 40 | 2019-08-06 | 2021-09-01 |
| Comparison of Two Diagnostic Tests in Patients With Suspected Invasive Candidiasis in Internal Medicine Wards and Who Are Currently Timely Treated With Micafungin 1,3-β-D-glucan quantification, Micafungin - Invasive Candidiasis | Phase 4 | Terminated | Fadoi Foundation, Italy | 14 | 2018-07-18 | 2021-04-12 |
| Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever) Fluconazole, Placebo - Coccidioidomycosis | Phase 4 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 72 | 2015-12-29 | 2019-07-05 |
| Amphotericin-B and Voriconazole for Pulmonary Blastomycosis amphotericin-B, voriconazole - Blastomycosis | Phase 4 | Terminated | University of Manitoba | 2 | 2015-06-01 | 2020-09-29 |
| Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp Micafungin - Aspergillosis, Candidiasis | Phase 4 | Terminated | Astellas Pharma China, Inc. | 105 | 2014-03-21 | 2024-11-07 |
| Post Marketing Study to Evaluate the Efficacy and Safety of Micafungin Treatment on Invasive Aspergillosis Micafungin - Invasive Aspergillosis | Phase 4 | Terminated | Astellas Pharma China, Inc. | 43 | 2014-03-01 | 2024-11-20 |
| A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia Micafungin - Candidemia, Candidiasis | Phase 4 | Terminated | Astellas Pharma China, Inc. | 59 | 2013-09-26 | 2024-11-20 |
| A Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients (MK-5592-105) Posaconazole, Calogen® - Fungal Infection | Phase 4 | Terminated | Merck Sharp & Dohme LLC | 26 | 2013-01-23 | 2018-10-09 |
| Evaluation of Antifungal Prophylaxis on Graft-versus-host Disease (GVHD) Patients Itraconazole - Graft vs Host Disease | Phase 4 | Terminated | Samsung Medical Center | 36 | 2009-12-01 | 2011-01-25 |
| An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA) Omalizumab, Placebo, Itraconazole - Cystic Fibrosis, Allergic Bronchopulmonary Aspergillosis | Phase 4 | Terminated | Novartis Pharmaceuticals | 14 | 2008-11-01 | 2011-09-26 |
| Safety Study of Ciclopirox Olamine Cream for Dermatomycoses in Children ciclopirox - Dermatomycoses | Phase 4 | Terminated | Ferrer Internacional S.A. | 21 | 2008-10-01 | 2012-07-20 |
| Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene) voriconazole, anidulafungin - Aspergillosis | Phase 4 | Terminated | Pfizer | 6 | 2008-08-01 | 2010-02-15 |
| ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifungal Infections in Elderly Patients With Acute Lymphoblastic Leukemia liposomal amphotericin B (AmBisome®) - Fungal Infection | Phase 4 | Terminated | Gilead Sciences | 20 | 2006-11-01 | 2007-08-21 |
| Limited Access Protocol of Posaconazole in Invasive Fungal Infections Study PO2095 Posaconazole - Fungal Infection | Phase 4 | Terminated | University of Pittsburgh | 10 | 2004-08-01 | 2008-12-17 |
| Comparison of 2 Antifungal Treatment (Empirical Versus Pre-Empirical) Strategies in Prolonged Neutropenia Amphotericin B - Malignant Hemopathy, Duration of Neutropenia Following Chemotherapy > 10 Days | Phase 4 | Terminated | Assistance Publique - Hôpitaux de Paris | 300 | 2003-04-01 | 2006-09-21 |
Aspergillosis (4) · Candidiasis (3) · Invasive Fungal Infections (2) · Aspergillosis, Allergic Bronchopulmonary (1) · Blastomycosis (1) · Candidemia (1) · Candidiasis, Invasive (1) · Coccidioidomycosis (1) · Community-Acquired Pneumonia (1) · Cystic Fibrosis (1) · Dermatomycoses (1) · Graft vs Host Disease (1) · Pneumonia (1) · Tinea (1)
Bacterial Infections and Mycoses (15) · Infections (15) · Lung Diseases (3) · Respiratory Tract Diseases (3) · Respiratory Tract Infections (3) · Immune System Diseases (2) · Invasive Fungal Infections (2) · Lung Diseases, Fungal (2) · Skin Diseases (2) · Skin Diseases, Infectious (2) · Skin and Connective Tissue Diseases (2) · Aspergillosis (1) · Candidiasis (1) · Candidiasis, Invasive (1)
Micafungin (4) · Itraconazole (3) · Amphotericin B (2) · Voriconazole (2) · posaconazole (2) · Anidulafungin (1) · Ciclopirox (1) · Fluconazole (1) · Omalizumab (1) · liposomal amphotericin B (1)
Astellas Pharma China, Inc. (3) · Assistance Publique - Hôpitaux de Paris (1) · Fadoi Foundation, Italy (1) · Ferrer Internacional S.A. (1) · Gilead Sciences (1) · Janssen Research & Development, LLC (1) · Merck Sharp & Dohme LLC (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Novartis Pharmaceuticals (1) · Pfizer (1) · Samsung Medical Center (1) · University of Manitoba (1) · University of Pittsburgh (1)
China (3) · United States (3) · Germany (2) · Italy (2) · Belgium (1) · Canada (1) · France (1) · India (1) · Netherlands (1) · South Korea (1) · United Kingdom (1)
Catherine Hardalo, MD (1) · Dong Hwan Kim, M.D./Ph.D. (1) · Jose C Moreno, Prof, PhD (1) · Mark Sampson (1) · Robert E. Ariano, Pharm.D. (1)
PMID 12729424, PMID 1542320, PMID 26302738, PMID 36787305
2008 (1)